Immunotherapy targeting EBV-expressing lymphoproliferative diseases

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 3, 2008, Pages 405-420

  Bollard, Catherine M ^a   Cooper, Laurence J ^b   Heslop, Helen E ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

chimeric antigen receptors; cytotoxic T lymphocytes; EBV; post transplant lymphoproliferative disease

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; FLUDARABINE; INTERLEUKIN 2; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; RITUXIMAB; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BURKITT LYMPHOMA; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; EPSTEIN BARR VIRUS; GENETIC MANIPULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOTHERAPY; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MEMORY CELL; NONHODGKIN LYMPHOMA; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RELAPSE; REVIEW; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; VIRUS LATENCY; VIRUS LOAD;

ANTIBODIES, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE TRANSFUSION; LYMPHOMA; LYMPHOMA, NON-HODGKIN; LYMPHOPROLIFERATIVE DISORDERS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VIRUS LATENCY;

EID: 51349096949     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.06.002     Document Type: Review

References (70)

1. Rickinson A.B., and Kieff E. Epstein-Barr virus. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields Virology (1996), Lipincott-Raven, Philadelphia 2397-2446
2. Henle G., Henle W., and Horwitz C. Antibodies to Epstein-Barr virus-associated antigens in infectious mononucleosis. Journal of Infectious Diseases 130 (1974) 231-239
3. Young L.S., and Rickinson A.B. Epstein-Barr virus: 40 years on. Nature Reviews. Cancer 4 (2004) 757-768
4. Curtis R.E., Travis L.B., Rowlings P.A., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94 (1999) 2208-2216
5. Gottschalk S., Rooney C.M., and Heslop H.E. Post-transplant lymphoproliferative disorders. Annual Review of Medicine 56 (2005) 29-44
6. Nalesnik M.A. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results in Cancer Research 159 (2002) 9-18
7. Paya C.V., Fung J.J., Nalesnik M.A., et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68 (1999) 1517-1525
8. Milpied N., Vasseur B., Parquet N., et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Annals of Oncology 11 Suppl. 1 (2000) 113-116
9. Kuehnle I., Huls M.H., Liu Z., et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95 (2000) 1502-1505
10. Brunstein C.G., Weisdorf D.J., DeFor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108 (2006) 2874-2880
11. Savoldo B., Rooney C.M., Quiros-Tejeira R.E., et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. American Journal of Transplantation 5 (2005) 566-572
12. Choquet S., Oertel S., Leblond V., et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Annals of Hematology 86 (2007) 599-607
13. Papadopoulos E.B., Ladanyi M., Emanuel D., et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New England Journal of Medicine 330 (1994) 1185-1191
14. Heslop H.E., Brenner M.K., and Rooney C.M. Donor T cells to treat EBV-associated lymphoma. New England Journal of Medicine 331 (1994) 679-680
15. Rooney C.M., Smith C.A., Ng C., et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345 (1995) 9-13
16. Rooney C.M., Smith C.A., Ng C.Y.C., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92 (1998) 1549-1555
17. Heslop H.E., Ng C.Y.C., Li C., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Medicine 2 (1996) 551-555
18. Gustafsson A., Levitsky V., Zou J.Z., et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95 (2000) 807-814
19. Comoli P., Basso S., Zecca M., et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. American Journal of Transplantation 7 (2007) 1648-1655
20. Gottschalk S., Ng C.Y.C., Smith C.A., et al. An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 97 (2001) 835-843
21. Savoldo B., Goss J.A., Hammer M.M., et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108 (2006) 2942-2949
22. Comoli P., Labirio M., Basso S., et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99 (2002) 2592-2598
23. Khanna R., Bell S., Sherritt M., et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 10391-10396
24. Sherritt M.A., Bharadwaj M., Burrows J.M., et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 75 (2003) 1556-1560
25. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110 (2007) 1123-1131
26. Gandhi M.K., Wilkie G.M., Dua U., et al. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. American Journal of Transplantation 7 (2007) 1293-1299
27. Heslop H.E. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology (American Society of Hematology. Education Program) (2005) 260-266
28. Ambinder R.F., Lemas M.V., Moore S., et al. Epstein-Barr virus and lymphoma. Cancer Treatment and Research 99 (1999) 27-45
29. Brauninger A., Hansmann M.L., Strickler J.G., et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. New England Journal of Medicine 340 (1999) 1239-1247
30. Ambinder R.F. Epstein-Barr virus and Hodgkin lymphoma. Hematology (American Society of Hematology. Education Program) (2007) 204-209
31. Baker K.S., Gordon B.G., Gross T.G., et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. Journal of Clinical Oncology 17 (1999) 825-831
32. Ladenstein R., Pearce R., Hartmann O., et al. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 90 (1997) 2921-2930
33. Bollard C.M., Aguilar L., Straathof K.C., et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's disease. Journal of Experimental Medicine 200 (2004) 1623-1633
34. Straathof K.C., Leen A.M., Buza E.L., et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. Journal of Immunology 175 (2005) 4137-4147
35. Cho H.I., Hong Y.S., Lee M.A., et al. Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. International Journal of Hematology 83 (2006) 66-73
36. Lucas K.G., Salzman D., Garcia A., et al. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 100 (2004) 1892-1901
37. Gahn B., Siller-Lopez F., Pirooz A.D., et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to the LMP2A-antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. International Journal of Cancer 93 (2001) 706-713
38. Gottschalk S., Edwards O.L., Sili U., et al. Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 101 (2003) 1905-1912
39. Su Z., Peluso M.V., Raffegerst S.H., et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. European Journal of Immunology 31 (2001) 947-958
40. Orentas R.J., Roskopf S.J., Nolan G.P., et al. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clinical immunology 98 (2001) 220-228
41. Bollard C.M., Straathof K.C., Huls M.H., et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. Journal of Immunotherapy 27 (2004) 317-327
42. Bollard C.M., Gottschalk S., Leen A.M., et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110 (2007) 2838-2845
43. Heller K.N., Upshaw J., Seyoum B., et al. Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood 109 (2007) 1138-1146
44. Poppema S. Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology (American Society of Hematology. Education Program) (2005) 231-238
45. Dukers D.F., Jaspars L.H., Vos W., et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. Journal of Pathology 190 (2000) 143-149
46. Skinnider B.F., Elia A.J., Gascoyne R.D., et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 97 (2001) 250-255
47. Gorelik L., and Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nature Medicine 7 (2001) 1118-1122
48. Bollard C.M., Rossig C., Calonge M.J., et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99 (2002) 3179-3187
49. Lacuesta K., Buza E., Hauser H., et al. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. Journal of Immunotherapy 29 (2006) 250-260
50. Dustin M.L. T-cell activation through immunological synapses and kinapses. Immunological Reviews 221 (2008) 77-89
51. Eshhar Z., Waks T., Gross G., et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America 90 (1993) 720-724
52. Pameijer C.R., Navanjo A., Meechoovet B., et al. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Therapy 14 (2007) 91-97
53. Sadelain M., Riviere I., and Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nature Reviews. Cancer 3 (2003) 35-45
54. Zakrzewski J.L., Suh D., Markley J.C., et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nature Biotechnology 26 (2008) 453-461
55. Brentjens R.J., Latouche J.B., Santos E., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Medicine 9 (2003) 279-286
56. Wang J., Press O.W., Lindgren C.G., et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Molecular Therapy 9 (2004) 577-586
57. Cooper L.J., Al Kadhimi Z., Serrano L.M., et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 105 (2005) 1622-1631
58. Savoldo B., Rooney C.M., Di S.A., et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 110 (2007) 2620-2630
59. Kershaw M.H., Westwood J.A., Parker L.L., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research 12 (2006) 6106-6115
60. Park J.R., Digiusto D.L., Slovak M., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Molecular Therapy 15 (2007) 825-833
61. Lamers C.H., Langeveld S.C., Groot-van Ruijven C.M., et al. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunology, Immunotherapy 56 (2007) 1875-1883
62. Berger C., Jensen M.C., Lansdorp P.M., et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. Journal of Clinical Investigation 118 (2008) 294-305
63. Stephan M.T., Ponomarev V., Brentjens R.J., et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature Medicine 13 (2007) 1440-1449
64. Quintarelli C., Vera J.F., Savoldo B., et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 110 (2007) 2793-2802
65. Rossig C., Bollard C.M., Nuchtern J.G., et al. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99 (2002) 2009-2016
66. Muranski P., Boni A., Wrzesinski C., et al. Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go?. Nature Clinical Practice. Oncology 3 (2006) 668-681
67. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
68. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005) 3051-3057
69. Sun Q., Burton R., Reddy V., et al. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. British Journal of Haematology 118 (2002) 799-808
70. Roskrow M.A., Rooney C.M., Heslop H.E., et al. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Human Gene Therapy 9 (1998) 1237-1250